STAT3-IN-12 is a small molecule inhibitor specifically designed to target the Signal Transducer and Activator of Transcription 3 (STAT3) pathway, which plays a crucial role in various cellular processes, including cell growth, survival, and differentiation. This compound is of particular interest in cancer research due to its potential to disrupt the aberrant signaling associated with tumor progression and immune evasion. STAT3-IN-12 exhibits characteristics typical of small molecule inhibitors, such as a defined molecular structure that allows for selective binding to the STAT3 protein, thereby inhibiting its activity. The compound's efficacy and specificity are often evaluated through various biochemical assays and cellular models. Additionally, its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), are critical for determining its potential therapeutic applications. Research into STAT3-IN-12 continues to explore its role in cancer therapy and other diseases where STAT3 is implicated, making it a subject of interest in the field of medicinal chemistry and drug development.

STAT3-IN-12

2980758-31-2: STAT3-IN-12 is a small molecule inhibitor specifically designed to target the Signal Transducer and Activator of Transcription 3 (STAT3) pathway, which plays a crucial role in various cellular processes, including cell growth, survival, and differentiation. This compound is of particular interest in cancer research due to its potential to disrupt the aberrant signaling associated with tumor progression and immune evasion. STAT3-IN-12 exhibits characteristics typical of small molecule inhibitors, such as a defined molecular structure that allows for selective binding to the STAT3 protein, thereby inhibiting its activity. The compound's efficacy and specificity are often evaluated through various biochemical assays and cellular models. Additionally, its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), are critical for determining its potential therapeutic applications. Research into STAT3-IN-12 continues to explore its role in cancer therapy and other diseases where STAT3 is implicated, making it a subject of interest in the field of medicinal chemistry and drug development.

2,6-Bis(3-methoxyphenyl)-1,7-dipropyl-1,7-dihydrobenzo[1,2-d:4,5-d']diimidazole

STAT3-IN-12,STAT3 signaling inhibitor. Blocks IL-6-induced JAK/STAT3 activation. Induces apoptosis. Used in HCC and esophageal cancer research.

CAS 2980758-31-2

STAT3-IN-12

2,6-Bis(3-methoxyphenyl)-1,7-dipropyl-1,7-dihydrobenzo[1,2-d:4,5-d']diimidazole

Ref: 54-OR1074600

STAT3-IN-12

Ref: TM-T62803